转化医学国家重大科技基础设施（上海）项目（简称大设施）于2013年7月经国家发展和改革委员会正式批准建设。2015年8月获国家发展和改革委员会正式批复。2016年9月正式启动建设。
作为国家级转化医学研究机构，大设施由国家教育部和上海市共同管理，是我国首个综合性国家级转化医学重大科技基础设施。大设施以国家创新战略和国家中长期科技发展规划为导向，以促进前沿技术和基础医学研究成果向临床应用转化为目标，结合上海交通大学和瑞金医院的研究基础和学科优势，选择严重危害中国人群健康的肿瘤、代谢性疾病和心脑血管疾病等“三大类疾病”作为主要研究对象。大设施将重点建设转化医学核心设施、资源深度开发与共享设施和关键技术支撑设施三大板块，与三大类疾病形成“三纵三横”的建设格局。
为满足4P（预测、预防、个体化和参与）医学的发展需要，转化医学核心设施将重点建设研究型病房和分子病理研究平台，努力提高我国临床研究的水平和质量，产生符合优秀临床实践（GCP）的标准化诊疗方案。资源深度开发与共享设施包括标准化临床生物样本库和队列样本库、临床资源深度开发平台和转化医学研究综合信息系统，为广大生命医学研究者共享珍贵临床样本资源、临床资料和相关信息提供便利，有效促进转化医学研究在我国的广泛开展。转化医学研究综合信息系统的建设包括运用现代生物信息学和生物统计学方法对临床、公共卫生和基础研究获得的大量数据进行高效分析和挖掘，探索和发现其中隐藏的生物医学规律，为广大临床和基础研究者提供一站式信息资源共享和信息分析处理服务。关键技术支撑设施包括生物标志物和药物靶标的发现与验证平台、新型药物与诊断试剂研究“前试”平台、诊疗药物和仪器开发平台、转化医学临床转化技术联合研究实验室和医理工协同创新实验室的建设。新生物标志物与药物靶标、新技术和产品通过发现、验证和“前试”后再回到研究型病房进行严格的临床试验。通过上述研究计划，大设施力争开发出一批新方法、新药物、新试剂、新仪器和新技术，促进三大类疾病的早期诊断、治疗和预防。
目前中心已初步建立起一支具有转化医学相关背景和工作经验、能胜任学科交叉融合的高层次专业技术人员队伍。
National Research Center for
Translational Medicine·Shanghai
——National Key Scientific Infrastructure for Translational Medicine
National Center for Translational Medicine·Shanghai (the Center for short hereinafter), which is a national key scientific infrastructure, has been formally approved to be founded by National Development and Reform Commission in July 2013. As a national academic institution, the Center is co-administrated by Ministry of Education and Shanghai Municipal Government.
With an aim to promote the translation of frontier technologies and the findings of basic medical research into clinical practices, the Center has adopted a “systematic three by three” research scheme. Guided by the National Innovation Strategies and National Mid- and Long-Term Guidelines for Scientific Development, and to make the best of the advantages of SJTU and Rui-Jin Hospital, the research of the Center will be focused on three major types of life-threatening diseases: cancer, cardiovascular and cerebrovascular diseases, and metabolic diseases.
To carry out the research, the Center will prioritize building three main platforms: translational research core facilities, a resource sharing system, and a key technical supporting system. The priorities of the translational research core facilities will be given to research wards and a pathological study platform, which are crucial for the development of 4P (predictive, preventive, personalized and participatory) medicine. This will aim to improve clinical studies in China and develop standardized diagnosis and treatment protocols that keep to the norms of good clinical practice. The resource-sharing system includes standardized bio-banks (clinical cases and cohort studies), platforms for in-depth development and utilization of clinical resources, and comprehensive bio-information systems, providing and sharing valuable clinical (cohort) samples and relevant information for researchers. Modern bioinformatics and biological statistics will be used to analyze data from clinical and basic research, explore and discover the hidden biomedical rules, and provide one-stop information resource-sharing and analysis for clinical and basic researchers. The key technical supporting system includes a discovery and validation platform for biological markers and drug targets, a “pre-trial” platform for new drugs and diagnostic reagents, an exploitation platform for combined targeting therapeutics, and a development platform of new medical instruments, joint research laboratories and collaborative innovation laboratories. After discovery, validation and pre-trial through the above platforms, the novel biomarkers, drug targets, the innovative technologies and products will be applied back to the research wards.
Presently, a high-level and multidisciplinary research team has been established.
